CABA Cabaletta Bio Inc

Price (delayed)

$1.01

Market cap

$29.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.84

Enterprise value

-$30.29M

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, ...

Highlights
Cabaletta Bio's quick ratio has decreased by 39% YoY but it has increased by 8% QoQ
The equity has contracted by 10% from the previous quarter but it has grown by 3.3% YoY
CABA's net income is down by 39% year-on-year and by 7% since the previous quarter
CABA's EPS is down by 25% YoY and by 2.2% QoQ

Key stats

What are the main financial stats of CABA
Market
Shares outstanding
28.98M
Market cap
$29.27M
Enterprise value
-$30.29M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$49.53M
EBITDA
-$48.7M
Free cash flow
-$39.46M
Per share
EPS
-$1.84
Free cash flow per share
-$1.36
Book value per share
$3.68
Revenue per share
$0
TBVPS
$3.92
Balance sheet
Total assets
$113.66M
Total liabilities
$6.94M
Debt
$0
Equity
$106.72M
Working capital
$104.5M
Liquidity
Debt to equity
0
Current ratio
16.07
Quick ratio
15.75
Net debt/EBITDA
1.22
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42.2%
Return on equity
-44.8%
Return on invested capital
-459.8%
Return on capital employed
-46.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CABA stock price

How has the Cabaletta Bio stock price performed over time
Intraday
-4.72%
1 week
-1.94%
1 month
-21.09%
1 year
-86.26%
YTD
-73.35%
QTD
-50.25%

Financial performance

How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.6M
Net income
-$49.53M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 39% YoY and by 7% from the previous quarter
CABA's net income is down by 39% year-on-year and by 7% since the previous quarter

Growth

What is Cabaletta Bio's growth rate over time

Valuation

What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
0.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is down by 25% YoY and by 2.2% QoQ
CABA's price to book (P/B) is 82% lower than its last 4 quarters average of 1.5
The equity has contracted by 10% from the previous quarter but it has grown by 3.3% YoY

Efficiency

How efficient is Cabaletta Bio business performance
The ROIC has soared by 95% from the previous quarter but it has contracted by 15% YoY
Cabaletta Bio's ROE has decreased by 43% YoY and by 6% from the previous quarter
Cabaletta Bio's return on assets has decreased by 40% YoY and by 6% QoQ

Dividends

What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CABA.

Financial health

How did Cabaletta Bio financials performed over time
Cabaletta Bio's total liabilities has soared by 75% YoY but it has decreased by 17% from the previous quarter
The current ratio has contracted by 40% YoY but it has grown by 8% from the previous quarter
CABA's debt is 100% smaller than its equity
The equity has contracted by 10% from the previous quarter but it has grown by 3.3% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.